^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) + I-BET151 (BRD4 inhibitor, BRD2 inhibitor, BRD3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NOVEL COMPOUNDS TO TARGET KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
Published date:
05/11/2023
Excerpt:
In attempt to target it, we tested novel drug combinations of venetoclax (VEN), a BCL- 2 inhibitor, with KMT2A-specific drugs, revealing that the Bromodomain and Extra-Terminal Domain (BET) inhibitor I-BET151, and the kinase inhibitor sunitinib, decreased BCL-2 family protein expression and synergized with VEN enhancing KMT2A-r AML cell death, also in the 3D model.
